Clinical Trial Update: Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH [Phase 3]

View source ↗

Summary

Phase 3 trial comparing burosumab to oral phosphate and active vitamin D in pediatric patients with X-linked hypophosphatemia; results assess efficacy and safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• Crysvita (burosumab)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: X-Linked Hypophosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2019-04-11